CHRISTOPHER COLECCHI

Christopher Colecchi serves as a Managing Director at Broadview Ventures, a leading venture capital firm singularly focused on driving innovation in ophthalmology and optometry. In this pivotal role, Mr. Colecchi is instrumental in identifying, evaluating, and investing in companies that are developing transformative therapies, cutting-edge devices, and advanced diagnostics to address a wide spectrum of eye diseases. His work directly contributes to Broadview Ventures' mission of funding solutions for conditions such as glaucoma, macular degeneration, diabetic retinopathy, dry eye, and various genetic ocular disorders.

Mr. Colecchi's investment focus at Broadview Ventures spans the entire ophthalmic landscape. He actively seeks out opportunities in novel drug delivery systems, gene therapies targeting inherited retinal diseases, innovative surgical tools, and diagnostic platforms that promise to improve patient outcomes. His expertise extends to both early-stage and growth-stage companies, providing strategic guidance and capital to help promising ventures navigate the complex development and commercialization pathways within the life sciences sector. He often serves on the boards of portfolio companies, offering hands-on support and leveraging his extensive network.

Before joining Broadview Ventures, Christopher Colecchi built a distinguished career in venture capital and life sciences. He previously held significant positions as a Partner at SV Health Investors and as a Principal at Flagship Ventures (now Flagship Pioneering), where he gained invaluable experience in biotech and medical technology investments across various therapeutic areas. This background provided him with a robust understanding of scientific innovation, clinical development, and market dynamics crucial for successful venture investing. Academically, Mr. Colecchi holds a Ph.D. in Biochemistry from Brandeis University and completed postdoctoral research at Harvard Medical School, underscoring his deep scientific foundation.

Throughout his career, Mr. Colecchi has been associated with numerous successful investments that have brought significant advancements to patient care. While at Broadview Ventures and his previous roles, he has been involved with companies that have developed groundbreaking treatments. Examples of companies he has been involved with include Apellis Pharmaceuticals, Graybug Vision, and Kala Pharmaceuticals, among others, demonstrating his track record in backing impactful innovations. His strategic insights and commitment to fostering scientific breakthroughs make him a key figure in the ophthalmic venture capital ecosystem, continually seeking to fund the next generation of solutions for vision health.